A practical reference on melanocortin receptor: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-12-02 and is reviewed periodically as new material appears.
Melanotan-2 is frequently confused with afamelanotide, a linear analogue authorised in the European Union for erythropoietic protoporphyria. The two compounds differ in chain length, ring structure and receptor selectivity, so findings for one cannot be transferred directly to the other. Published controlled human data on melanotan-2 remain sparse, and much of what circulates online derives from small studies or unpublished reports. Questions about effect size, dose-response behaviour and long-term safety therefore remain unresolved.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence incorporates a lactam bridge that constrains the peptide into a ring, which increases resistance to enzymatic breakdown relative to the natural hormone. Researchers at the University of Arizona synthesised the compound in the late 1980s and early 1990s while studying pigmentation pathways. It has never received marketing approval from any national medicines regulator. In the scientific literature it is usually described as a laboratory research reagent rather than a therapeutic product.
The peptide acts as a non-selective agonist at melanocortin receptors, showing affinity for MC1R, MC3R, MC4R and MC5R. Activation of MC1R on melanocytes drives the conversion of tyrosine into melanin and shifts production toward the darker eumelanin form. MC4R signalling in the central nervous system is linked to appetite and energy balance, which helps explain why reduced food intake appeared in early human studies. Effects on MC4R and on vascular tone also account for the erectile responses recorded as unexpected findings in those same trials.
Identity and purity are assessed with chromatographic and mass spectrometric techniques. Reversed-phase high-performance liquid chromatography separates the target peptide from related impurities and degradation products, and the resulting retention time is compared against a reference standard. Mass spectrometry, often coupled to liquid chromatography, confirms molecular mass. Amino acid analysis or peptide mapping can provide additional sequence-level confirmation when required. Results are only as reliable as the reference materials used alongside them.
Regulatory treatment varies by country. In the United States, melanotan-2 is not approved for any indication, and products marketed for human use fall outside the approved drug framework. Some other jurisdictions have placed it under prescription controls or listed it as a prohibited or restricted substance. Online listings frequently describe the material as a research chemical, a category that does not carry the same manufacturing and labelling requirements as approved medicines.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Alpha-MSH analogue with a lactam ring |
| Molecular formula | C50H69N15O9 | Commonly cited value for the neutral peptide |
| Molecular weight | 1024.18 g/mol | Calculated for the free molecule |
| Appearance | White to off-white powder | Typically supplied as a lyophilised solid |
| Solubility | Soluble in water, DMSO and ethanol | Dissolution in pure water is often slow |
No regulatory authority has approved melanotan-2 for human use, and several countries classify it as a prescription-only or controlled substance, which restricts lawful supply. Material sold online is generally labelled as a research chemical and is not required to meet pharmaceutical standards of identity or purity. Published human data consist mainly of small uncontrolled studies, case reports and adverse-event notifications, so the evidence base is descriptive rather than confirmatory. Whether repeated melanocyte stimulation alters long-term naevus behaviour remains an open question that no completed trial has resolved.
Melanotan-2 is a synthetic cyclic heptapeptide designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous tridecapeptide that regulates pigment production. Two modifications distinguish it from the natural hormone: norleucine replaces methionine at the N-terminus, which limits oxidation, and a D-phenylalanine substitution raises receptor affinity. The ring is closed through an aspartate-lysine lactam bridge, giving the molecule a constrained conformation. The free base has a molecular mass near 1024 daltons, and commercial material is usually supplied as an acetate salt. It appears in the literature as a research peptide rather than an approved therapeutic agent.
Regulatory status varies by jurisdiction, and the substance is frequently described as unapproved for therapeutic use. Some authorities classify it alongside prescription-only medicines or controlled categories, while others address it through general consumer protection rules. Analytical surveys have reported mismatches between label claims and measured content in products sold online, although the scope of such testing is limited. Whether these discrepancies are widespread remains an open question. Discussion in the literature therefore tends to combine chemistry, supply-chain observation and policy analysis.
The material is commonly handled as a lyophilized powder in sealed vials. The solid dissolves readily in water and in polar organic solvents, producing a clear solution after reconstitution. Light, heat and repeated freeze-thaw cycles are the concerns most often raised in handling guidance, because peptide bonds and the constrained ring can degrade. Working solutions are generally prepared fresh, and material left in solution is treated as less stable than the dry form. These properties shape how laboratories store and aliquot reference material.
The Defense Secretary threatened Anthropic, the owner of Claude AI (the only AI authorized by the Department of Defense in early 2026), to designate the company a supply chain risk and force the company to eliminate its restrictions on the use of its AI by the Defense Department or he will use the Defense Production Act to compel them. The Defense Department gave Anthropic a deadline of February 27, 2026. The contract Sec. Hegseth wanted to cancel was worth $200 million. A senior defense official stated that the company will "pay a price for forcing our hand like this." Anthropic stated that they wanted assurances that the DoD would not use their AI tools to spy on Americans or develop weapons that could fire without human involvement. The Defense Department also stated in February 2026 that Grok, OpenAI and Google were close to being approved for use. Claude was used by the Pentagon during their January 2026 operation to capture Nicolas Maduro. In May 2026, the Defense Department announced AI use deals with SpaceX, OpenAI, Google, NVIDIA, Reflection, Microsoft and Amazon Web Services. On February 27, 2026, Hegseth used the Federal Acquisition Supply Chain Security Act to declare Anthropic a supply chain risk and excluded it from all federal contracts. President Trump also stated that every federal agency must stop using Anthropic's AI technology. ChatGPT signed a deal with the Defense Department the same day but their CEO Sam Altman said, "the AI system shall not be intentionally used for domestic surveillance of U.S.
== Donor selection == When grafts are taken from other animals, they are known as heterografts or xenografts. By definition, they are temporary biologic dressings which the body will reject within days to a few weeks. They are useful in reducing the bacterial concentration of an open wound, as well as reducing fluid loss. For more extensive tissue loss, a full-thickness skin graft, which includes the entire thickness of the skin, may be necessary. This is often performed for defects of the face and hand where contraction of the graft should be minimized. The general rule is that the thicker the graft, the less the contraction and deformity. Cell cultured epithelial autograft (CEA) procedures take skin cells from the person needing the graft to grow new skin cells in sheets in a laboratory; because the cells are taken from the person, that person's immune system will not reject them. However, because these sheets are very thin (only a few cell layers thick) they do not stand up to trauma, and the "take" is often less than 100%. Newer grafting procedures combine CEA with a dermal matrix for more support.Research is investigating the possibilities of combining CEA and a dermal matrix in one product. Experimental procedures are being tested for burn victims using stem cells in solution which are applied to the burned area using a skin cell gun. Recent advances have been successful in applying the cells without damage.
=== Galactose metabolism === No direct catabolic pathways exist for galactose metabolism. Galactose is therefore preferentially converted into glucose-1-phosphate, which may be shunted into glycolysis or the inositol synthesis pathway. GALE functions as one of four enzymes in the Leloir pathway of galactose conversion of glucose-1-phosphate. First, galactose mutarotase converts β-D-galactose to α-D-galactose. Galactokinase then phosphorylates α-D-galactose at the 1' hydroxyl group, yielding galactose-1-phosphate. In the third step, galactose-1-phosphate uridyltransferase catalyzes the reversible transfer of a UMP moiety from UDP-glucose to galactose-1-phosphate, generating UDP-galactose and glucose-1-phosphate. In the final Leloir step, UDP-glucose is regenerated from UDP-galactose by GALE; UDP-glucose cycles back to the third step of the pathway. As such, GALE regenerates a substrate necessary for continued Leloir pathway cycling. The glucose-1-phosphate generated in step 3 of the Leloir pathway may be isomerized to glucose-6-phosphate by phosphoglucomutase. Glucose-6-phosphate readily enters glycolysis, leading to the production of ATP and pyruvate. Furthermore, glucose-6-phosphate may be converted to inositol-1-phosphate by inositol-3-phosphate synthase, generating a precursor needed for inositol biosynthesis.
E. coli is one of the most widely used expression hosts, and DNA is normally introduced in a plasmid expression vector. The techniques for overexpression in E. coli are well developed and work by increasing the number of copies of the gene or increasing the binding strength of the promoter region so assisting transcription. For example, a DNA sequence for a protein of interest could be cloned or subcloned into a high copy-number plasmid containing the lac (often LacUV5) promoter, which is then transformed into the bacterium E. coli. Addition of IPTG (a lactose analog) activates the lac promoter and causes the bacteria to express the protein of interest. E. coli strain BL21 and BL21(DE3) are two strains commonly used for protein production. As members of the B lineage, they lack lon and OmpT proteases, protecting the produced proteins from degradation. The DE3 prophage found in BL21(DE3) provides T7 RNA polymerase (driven by the LacUV5 promoter), allowing for vectors with the T7 promoter to be used instead.
Sources: en.wikipedia.org
During this civil war, which ended the Commune, many other Parisian buildings burned, sometimes accidentally due to artillery fire from both sides. In mere hours, centuries of history were destroyed, including the Tuileries Palace, Palais-Royal, Orsay Palace (seat of the Court of Accounts), the Ministry of Finance, the Palace of the Legion of Honor (where many records of honorees were lost), the Police Prefecture, the Louvre Library, the General Warehouses, Gare de Lyon, and the home of Prosper Mérimée at 52 Rue de Lille, which housed his correspondence and part of his library. However, some buildings escaped destruction: the National Archives were saved by Louis-Guillaume Debock, who stopped his Communard comrades from setting them ablaze; the Louvre Museum; the Sainte-Chapelle, already doused in petroleum; Notre-Dame, where interns from Hôtel-Dieu extinguished a fire; and the Granary of Abundance at the Arsenal Basin. Prior to the destruction of City Hall and the Palais de Justice, Paris' archives included:
== Reaction mechanism == The methylglyoxal molecule consists of two carbonyl groups flanked by a hydrogen atom and a methyl group. In the discussion below, these two carbonyl carbons will be denoted as C1 and C2, respectively. In both the hemithioacetal substrate and the (R)-S-lactoylglutathione product, the glutathione moiety is bonded to the C1 carbonyl group. The basic mechanism of glyoxalase I is as follows. The substrate hemithioacetal is formed when a molecule of glutathione — probably in its reactive thiolate form — attacks the C1 carbonyl of methylglyoxal or a related compound, rendering that carbon tetravalent. This reaction occurs spontaneously in the cell, without the involvement of the enzyme. This hemithioacetal is then bound by the enzyme, which shifts a hydrogen from C1 to C2. The C2 carbonyl is reduced to a tetravalent alcohol form by the addition of two protons, whereas the C1 carbonyl is restored by losing a hydrogen while retaining its bond to the glutathione moiety. A computational study, combined with the available experimental data, suggests the following atomic-resolution mechanism for glyoxalase I. In the active site, the catalytic metal adopts an octahedral coordination geometry and, in the absence of substrate, binds two waters, two opposite glutamates, a histidine and one other sidechain, usually another histidine or glutamates. When the substrate enters the active site, the two waters are shed and the two carbonyl oxygens of the substrate are bound directly to the metal ion.
=== Gastrointestinal distress === Nausea, vomiting, anorexia, diarrhea, abdominal cramps, and constipation are common side-effects of chemotherapeutic medications that kill fast-dividing cells. Malnutrition and dehydration can result when the recipient does not eat or drink enough, or when the person vomits frequently, because of gastrointestinal damage. This can result in rapid weight loss, or occasionally in weight gain, if the person eats too much in an effort to allay nausea or heartburn. Weight gain can also be caused by some steroid medications. These side-effects can frequently be reduced or eliminated with antiemetic drugs. Low-certainty evidence also suggests that probiotics may have a preventative and treatment effect of diarrhoea related to chemotherapy alone and with radiotherapy. However, a high index of suspicion is appropriate, since diarrhoea and bloating are also symptoms of typhlitis, a very serious and potentially life-threatening medical emergency that requires immediate treatment.
As a consequence, the editosome can edit only in a 3' to 5' direction along the primary RNA transcript. The complex can act on only a single guide RNA at a time. Therefore, a RNA transcript requiring extensive editing will need more than one guide RNA and editosome complex.
== Drug Interactions == Increased risk of adverse effects when used with alcohol. May potentiate the effects of general anaesthetics and anticoagulants, and prolong the action of neuromuscular blockers. May increase anticholinergic effects of atropine and drugs with anticholinergic activity. May increase risk of neurotoxicity when used with sibutramine or lithium. Avoid concurrent usage with drugs that cause QT prolongation or cardiac arrhythmias. May inhibit metabolism of TCAs. May antagonise effects of adrenaline and sympathomimetics, and reverse antihypertensive effects of guanethidine.
Sources: en.wikipedia.org
24 May – Andrew Shaw, children's television presenter, television director and producer (South Pacific Television, TVNZ), and media executive (TVNZ, South Pacific Pictures, NZ On Air) (born 1957). 29 May – David Trist, cricketer (Canterbury) and cricket coach (Eastern Province, national team) (born 1947). 30 May – John Pike, lawyer, King's Counsel (since 2013) (born 1944).
Thirdly, proteins may be separated by polarity/hydrophobicity via high-performance liquid chromatography or reversed-phase chromatography. Usually, a protein purification protocol contains one or more chromatographic steps. The basic procedure in chromatography is to flow the solution containing the protein through a column packed with various materials. Different proteins interact differently with the column material, and can thus be separated by the time required to pass the column, or the conditions required to elute the protein from the column. Proteins are typically detected as they are coming off the column by their absorbance at 280 nm. Many different chromatographic methods exist:
=== High-altitude radiation === In 1912, Victor Franz Hess (1883-1964) discovered (secondary) cosmic rays in the Earth's atmosphere using balloon flights. For this discovery he received the Nobel Prize in Physics in 1936. He was also one of the "martyrs" of early radiation research and had to undergo a thumb amputation and larynx surgery due to radium burns. In the United States and the Soviet Union, balloon flights to altitudes of about 30 km, followed by parachute jumps from the stratosphere, were conducted before 1960 to study human exposure to cosmic radiation in space. The American Manhigh and Excelsior projects with Joseph Kittinger (1928-2022) became particularly well known, but the Soviet parachutist Yevgeny Andreyev (1926-2000) also set new records.
== Case Study: Ocean Euxinia == Because green-pigmented green sulfur bacteria require higher light intensities than their brown-pigmented counterparts, the presence of chlorobactane in the rock record has been used as key evidence in interpretations for a very shallow euxinic layer in the ocean. The euxinic zone may have changed depth in the ocean at various points in Earth's history, such as with the advent of an oxygenated atmosphere around 2.45 billion years ago and the shallowing of the oxic zone within the last six kyr.
=== 1928–1999 === In 1928, June Hobbs and a nurse opened Lake Wales' first hospital; it had nine beds and was in a two-story apartment. About one year later it closed. In 1929, Lake Wales, Highland Park and Mountain Lake raised $80,000 to build a 25-bed hospital. Lake Wales Hospital opened on March 12, 1930. Additional bedrooms were added in 1948 and 1956, increasing the number of beds to 60. In 1965, a new 110-bed hospital was built. Nine years later the third floor opened, increasing the number of beds to 154, and the original hospital became a medical office building. In 1985, construction workers began the construction of the Deeley A. Hunt Building, a 120-bed nursing home attached to the hospital. In 1993, Lake Wales Hospital merged with its nursing home and was renamed Lake Wales Medical Centers. Also in 1993, the hospital became part of Mid Florida Medical Services. In late November 1999, the Winter Haven Hospital Board of Trustees voted unanimously on expansion and renovation of Lake Wales Medical Center. They also approved the demolition of the former hospital.
Sources: en.wikipedia.org
It is a synthetic cyclic heptapeptide modelled on alpha-melanocyte-stimulating hormone. A lactam bridge links two side chains, forming a ring that stabilises the molecule against proteolysis. It belongs to the broader melanocortin peptide family.
No national medicines agency has approved melanotan-2 for clinical use. Afamelanotide, a related but distinct peptide, holds a marketing authorisation in the European Union for a rare photosensitivity disorder. Melanotan-2 itself is handled as a laboratory chemical.
Its broad activity across melanocortin receptors makes it a tool for probing pigmentation, appetite and vascular signalling. Early trials recorded skin darkening and other effects that were not the original focus of the work. Those observations generated hypotheses that later studies have examined.
Laboratory confirmation typically combines retention time matching on a chromatographic system with mass measurement. A reference standard of known identity is needed for a meaningful comparison. Sequence-level techniques can add further confirmation.